Transthyretin Amyloid Cardiomyopathy Treatment

While there is no options for Transthyretin Amyloid Cardiomyopathy Treatment, available treatments can help control symptoms and potentially slow disease progression. Treatment options include:

Medications: Diuretics help manage fluid retention. Beta-blockers and ACE inhibitors may help the heart pump more effectively.

Device-based therapies: A pacemaker or implantable cardioverter defibrillator (ICD) can treat irregular heart rhythms.

Liver transplantation : For certain types of hereditary ATTR-CM, replacing the liver can stop further production of problematic TTR protein. Considered high-risk with limited longevity benefits.

Tafamidis : The first medication approved by the FDA to treat ATTR-CM. It binds to and stabilizes TTR tetramers to prevent dissociation and amyloid formation. Associated with reduced mortality and cardiovascular hospitalizations.

Inotersen and Patisiran : Two RNA interference drugs approved for hereditary forms that prevent production of problematic TTR protein. Associated with substantial reductions in TTR levels and improved outcomes.

Get more insights on https://www.ukwebwire.com/transthyretin-amyloid-cardiomyopathy-treatment-market-growth-and-trnds-analysis-share-size-demand-forecast//